Skip to content

Study · Not a test of the peptide alone · 2025

5 results

Efficacy and Safety Assessment of ThriveCo Scar Fader Gel With Scarcede™ in the Treatment of Skin Scars.

Patel MN, Patel N, Merja A, Patnaik S, Maulekhi S

Cureus25 Aug 2025

PMID41001334 (opens in a new tab)PMCIDPMC12459080 (opens in a new tab)DOI10.7759/cureus.90934 (opens in a new tab)PepBankPUB-41001334
Download PDFPubMedAsk about this study
Jump to 5 results

Summary

Introduction Skin scars, a natural outcome of dermal injury healing, may seem minor but often lead to significant disfigurement and psychological distress. This study aimed to assess the safety and efficacy of ThriveCo Scar Fader Gel containing Scarcede™ (Anveya Living Private Limited, Bengaluru, India), a proprietary blend of copper tripeptide-1, L-carnitine L-tartrate, alpha-glucosyl hesperidin, and sodium hyaluronate. This synergistic formulation targets multiple scar-improvement mechanisms, offering potential for enhanced skin texture and minimized scar appearance. Method An open-label, interventional, prospective real-world evidence study was conducted to evaluate the clinical safety, efficacy, and in-use tolerability of the test product in females with acne scars. Ethical approval was granted by the Independent Ethics Committee, and informed consent was obtained from all participants. Visible scar changes were assessed using the Manchester Scoring Scale by a dermatologist. Skin texture changes, including smoothness, roughness, and scaliness, were evaluated using VISIOSCAN® VC20 Plus (Courage + Khazaka electronic GmbH, Cologne, Germany). Digital photographs documented progressive scar visibility reduction. Statistical analyses were performed using IBM SPSS Statistics for Windows, Version 29.0.1.0 (Released 2022; IBM Corp., Armonk, New York) and Microsoft® Excel 2019 (Microsoft Corporation, Redmond, Washington), with significance reported at the 5% level. Result The test product reduced scar appearance by 7.17% at day 21 (p<0.001) and 26.57% at day 45 (p<0.0001). Skin smoothness improved by 33.08% at day 21 (p<0.0001) and 44.56% at day 45 (p<0.0001). Skin roughness decreased by 100.86% at day 21 (p<0.0001) and 161.62% at day 45 (p<0.0001). Scaliness reduced by 39.71% at day 21 (p<0.001) and 58.92% at day 45 (p<0.0001). No local or systemic adverse effects were reported. Conclusion ThriveCo Scar Fader Gel with Scarcede™ demonstrated clinical safety and efficacy in scar reduction, supporting smoother, clearer skin without adverse effects and suitable for routine skincare use.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, GHK-Cu was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHK-Cu.

  1. 01HumanNot a test of GHK-Cu aloneNon-randomized trialEfficacy outcome

    In females with acne scars, a gel containing a blend of copper tripeptide-1, L-carnitine, a flavonoid and hyaluronate reduced scar appearance by 7.17% at day 21 and 26.57% at day 45.

    In plain wordsIn women with acne scars, a gel with four active ingredients made scars look less visible over 45 days.

    Peptide
    GHK-Cu
    Outcome
    DecreaseScar appearance (Manchester Scoring Scale)
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Skin and hair · Skin and wound

    Measurements

    Scar appearance reduction
    7.17%
    day 21
    Scar appearance reduction
    26.57%
    day 45

    Source sentences

    Summary
    Result The test product reduced scar appearance by 7.17% at day 21 (p<0.001) and 26.57% at day 45 (p<0.0001).
    2 context sentences
    Summary · context
    This study aimed to assess the safety and efficacy of ThriveCo Scar Fader Gel containing Scarcede™ (Anveya Living Private Limited, Bengaluru, India), a proprietary blend of copper tripeptide-1, L-carnitine L-tartrate, alpha-glucosyl hesperidin, and sodium hyaluronate.
    Summary · context
    Method An open-label, interventional, prospective real-world evidence study was conducted to evaluate the clinical safety, efficacy, and in-use tolerability of the test product in females with acne scars.

    In this study, GHK-Cu was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHK-Cu.

  2. 02HumanNot a test of GHK-Cu aloneNon-randomized trialEfficacy outcome

    In females with acne scars, a gel containing a blend of copper tripeptide-1 and other actives improved skin smoothness by 33.08% at day 21 and 44.56% at day 45.

    In plain wordsIn women with acne scars, a gel with four active ingredients made skin smoother over 45 days.

    Peptide
    GHK-Cu
    Outcome
    IncreaseSkin smoothness
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Skin and hair · Skin and wound

    Measurements

    Smoothness improvement
    33.08%
    day 21
    Smoothness improvement
    44.56%
    day 45

    Source sentences

    Summary
    Skin smoothness improved by 33.08% at day 21 (p<0.0001) and 44.56% at day 45 (p<0.0001).
    2 context sentences
    Summary · context
    This study aimed to assess the safety and efficacy of ThriveCo Scar Fader Gel containing Scarcede™ (Anveya Living Private Limited, Bengaluru, India), a proprietary blend of copper tripeptide-1, L-carnitine L-tartrate, alpha-glucosyl hesperidin, and sodium hyaluronate.
    Summary · context
    Method An open-label, interventional, prospective real-world evidence study was conducted to evaluate the clinical safety, efficacy, and in-use tolerability of the test product in females with acne scars.

    In this study, GHK-Cu was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHK-Cu.

  3. 03HumanNot a test of GHK-Cu aloneNon-randomized trialEfficacy outcome

    In females with acne scars, a gel containing a blend of copper tripeptide-1 and other actives decreased skin roughness by 100.86% at day 21 and 161.62% at day 45.

    In plain wordsIn women with acne scars, a gel with four active ingredients reduced skin roughness over 45 days.

    Peptide
    GHK-Cu
    Outcome
    DecreaseSkin roughness
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Skin and hair · Skin and wound

    Measurements

    Roughness decrease
    100.86%
    day 21
    Roughness decrease
    161.62%
    day 45

    Source sentences

    Summary
    Skin roughness decreased by 100.86% at day 21 (p<0.0001) and 161.62% at day 45 (p<0.0001).
    2 context sentences
    Summary · context
    This study aimed to assess the safety and efficacy of ThriveCo Scar Fader Gel containing Scarcede™ (Anveya Living Private Limited, Bengaluru, India), a proprietary blend of copper tripeptide-1, L-carnitine L-tartrate, alpha-glucosyl hesperidin, and sodium hyaluronate.
    Summary · context
    Method An open-label, interventional, prospective real-world evidence study was conducted to evaluate the clinical safety, efficacy, and in-use tolerability of the test product in females with acne scars.

    In this study, GHK-Cu was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHK-Cu.

  4. 04HumanNot a test of GHK-Cu aloneNon-randomized trialEfficacy outcome

    In females with acne scars, a gel containing a blend of copper tripeptide-1 and other actives reduced scaliness by 39.71% at day 21 and 58.92% at day 45.

    In plain wordsIn women with acne scars, a gel with four active ingredients reduced skin scaliness over 45 days.

    Peptide
    GHK-Cu
    Outcome
    DecreaseSkin scaliness
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Skin and hair · Skin and wound

    Measurements

    Scaliness reduction
    39.71%
    day 21
    Scaliness reduction
    58.92%
    day 45

    Source sentences

    Summary
    Scaliness reduced by 39.71% at day 21 (p<0.001) and 58.92% at day 45 (p<0.0001).
    2 context sentences
    Summary · context
    This study aimed to assess the safety and efficacy of ThriveCo Scar Fader Gel containing Scarcede™ (Anveya Living Private Limited, Bengaluru, India), a proprietary blend of copper tripeptide-1, L-carnitine L-tartrate, alpha-glucosyl hesperidin, and sodium hyaluronate.
    Summary · context
    Method An open-label, interventional, prospective real-world evidence study was conducted to evaluate the clinical safety, efficacy, and in-use tolerability of the test product in females with acne scars.

    In this study, GHK-Cu was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHK-Cu.

  5. 05HumanNot a test of GHK-Cu aloneNon-randomized trialSafety outcome

    In females with acne scars, no local or systemic adverse effects were reported with a gel containing a blend of copper tripeptide-1 and other actives.

    In plain wordsIn women with acne scars, no side effects were reported with a gel that has four active ingredients.

    Peptide
    GHK-Cu
    Outcome
    No significant changeLocal or systemic adverse effects
    Study

    n: not reported in source

    Outcome group
    Adverse events · Skin and wound

    Source sentences

    Summary
    No local or systemic adverse effects were reported.
    2 context sentences
    Summary · context
    This study aimed to assess the safety and efficacy of ThriveCo Scar Fader Gel containing Scarcede™ (Anveya Living Private Limited, Bengaluru, India), a proprietary blend of copper tripeptide-1, L-carnitine L-tartrate, alpha-glucosyl hesperidin, and sodium hyaluronate.
    Summary · context
    Method An open-label, interventional, prospective real-world evidence study was conducted to evaluate the clinical safety, efficacy, and in-use tolerability of the test product in females with acne scars.

    In this study, GHK-Cu was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHK-Cu.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.